WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix will speak on using personal connected health for pain, addiction, and healing at the 2016 Connected Health Conference to take place Monday, December 12 in Washington, DC.
Chronic pain is estimated to impact about 20% of adults globally, and abuse of opioid painkillers is at epidemic levels in the US. Despite $20 billion in annual out of pocket spending, over half of consumers in the US are not satisfied with their pain relief. As a result, availability of technology-enabled approaches to treating pain are essential. Dr. Gozani will speak about the opportunities and challenges for connected wearable therapeutic devices in chronic pain.
“Chronic pain goes beyond the direct pain experience to alter sleep, activity, mood, and general health. Therefore, I was excited to see that the Connected Health Conference is addressing chronic pain this year,” said Dr. Gozani. “Our mission at NeuroMetrix, with the Quell® wearable pain relief device, is to provide chronic pain sufferers with technology that is drug-free and connected into a digital health platform that helps them manage their pain and improve their overall quality-of-life.”
About the Connected Health Conference
The Connected Health Conference, formerly the mHealth Summit, is the premier international conference and expo for the exchange of research, evidence, ideas, innovations and opportunities in connected health. In its eighth year, the event features industry-leading keynote presentations, four tracks of dynamic programming, poster presentations, an interactive exhibit floor, pre-conference symposia and high-value networking sessions. The Connected Health Conference is presented by the Personal Connected Health Alliance (PCHAlliance), a non-profit organization formed by HIMSS.
About Quell
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005764/en/
